FDA, on Monday, announced that it was reviewing whether a certain class of prostate cancer drugs could lead to diabetes, stroke, death, or heart problems.
The drugs in question are gonadotropin-Releasing Hormone (GnRH) agonists, marketed under a number of monikers, including Vantas and Lupron. These treatments are used to slow the growth of prostate cancer by decreasing the amount of testosterone created by the body.
“While our review of these prostate cancer treatments is ongoing and there are some limitations to the data, FDA believes it is important to tell patients and health care professionals that there may be an increased risk of serious side effects,” stated Robert Justice, director of the Division of Drug Oncology Products in FDA’s Center for Drug Evaluation and Research.
Doctors are being told not to suspend treatment, but to be aware of the risks and watch patients closely for diabetes of cardiovascular disease.